GlassScriptPhysician profile
Brian S Gerber
NPI 1487609343
$3,510.99
in general payments reported to CMS, 2019-2025
25 companies · $405 in 2025
The $405 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $279 · 2021: $638 · 2022: $744 · 2023: $683 · 2024: $434 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $791.13 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $586.01 | 2019-2025 | Xtandi |
| Pfizer INC. | $533.80 | 2019-2025 | |
| Abbvie INC. | $457.31 | 2019-2025 | |
| Janssen Biotech, INC. | $277.14 | 2019-2025 | Erleada, Akeega |
| Urovant Sciences INC | $149.12 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.00 | 2019-2024 | |
| Rochester Medical Corporation | $93.47 | 2021-2022 | |
| Boston Scientific Corporation | $73.67 | 2019-2021 | |
| Antares Pharma, INC. | $54.68 | 2021 | |
| Isoray, INC | $45.40 | 2019-2021 | |
| Blue Earth Diagnostics | $37.06 | 2021 | |
| Verity Pharmaceuticals INC. | $37.05 | 2023-2025 | Trelstar |
| Azurity Pharmaceuticals, INC. | $34.84 | 2023 | Adthyza |
| Coloplast Corp | $28.59 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $26.93 | 2021 | |
| Myovant Sciences INC. | $25.20 | 2021 | |
| Clarus Therapeutics INC. | $20.01 | 2021 | |
| Dentsply Ih Ab | $19.23 | 2025 | Lofric |
| Accord Healthcare, INC. | $17.08 | 2024 | |
| Zyla Life Sciences, INC. | $16.22 | 2019 | |
| Acella Pharmaceuticals, LLC | $15.64 | 2025 | NP Thyroid 60 |
| Kowa Pharmaceuticals America, INC. | $14.78 | 2022 | |
| Olympus America INC. | $12.58 | 2020 | |
| Convatec INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gerber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.